{
  "sources": {
    "cpic": "https://github.com/cpicpgx/cpic-data/releases/download/v1.10/cpic_db_dump-v1.10_inserts.sql.gz",
    "dpwg": "https://api.pharmgkb.org/v1/download/file/data/dosingGuidelines.json.zip",
    "fda": "https://raw.githubusercontent.com/PharmGKB/fda-biomarker/master/fda_pgx_associations_table.json"
  },
  "recommendations": {
    "cpic": {
      "abacavir": [
        {
          "factors": {
            "HLA-B*57:01": "negative"
          },
          "recommendation": "Use abacavir per standard dosing guidelines",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"
        },
        {
          "factors": {
            "HLA-B*57:01": "positive"
          },
          "recommendation": "Abacavir is not recommended",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-abacavir-and-hla-b/"
        }
      ],
      "allopurinol": [
        {
          "factors": {
            "HLA-B*58:01": "negative"
          },
          "recommendation": "Use allopurinol per standard dosing guidelines",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"
        },
        {
          "factors": {
            "HLA-B*58:01": "positive"
          },
          "recommendation": "Allopurinol is contraindicated",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-allopurinol-and-hla-b/"
        }
      ],
      "amikacin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "gentamicin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "kanamycin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "paromomycin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "plazomicin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "streptomycin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "tobramycin": [
        {
          "factors": {
            "MT-RNR1": "increased risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Avoid aminoglycoside anitbiotics unless the high risk of permanent hearing loss is outweighed by the severity of infection and lack of safe or effective alternative therapies.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "normal risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        },
        {
          "factors": {
            "MT-RNR1": "uncertain risk of aminoglycoside-induced hearing loss"
          },
          "recommendation": "Use aminoglycoside antibiotics at standard doses for the shortest feasible course with therapeutic dose monitoring. Evaluate regularly for hearing loss in line with local guidance.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-aminoglycosides-and-mt-rnr1/"
        }
      ],
      "escitalopram": [
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "amitriptyline": [
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If a amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use. If amitripyline is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid amitriptyline use; If amitriptyline is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "fluvoxamine": [
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "No recommendation due to lack of evidence",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Consider a 25-50% reduction of recommended starting dose and titrate to response or use an alternative drug not metabolized by CYP2D6.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "codeine": [
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Avoid codeine use because of potential for serious toxicity. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Avoid codeine use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Use codeine label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider a non-tramadol opioid.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        }
      ],
      "atazanavir": [
        {
          "factors": {
            "UGT1A1": "Normal Metabolizer"
          },
          "recommendation": "There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient\u2019s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"
        },
        {
          "factors": {
            "UGT1A1": "Intermediate Metabolizer"
          },
          "recommendation": "There is no need to avoid prescribing of atazanavir based on UGT1A1 genetic test result. Inform the patient that some patients stop atazanavir because of jaundice (yellow eyes and skin), but that this patient\u2019s genotype makes this unlikely (less than about a 1 in 20 chance of stopping atazanavir because of jaundice).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"
        },
        {
          "factors": {
            "UGT1A1": "Poor Metabolizer"
          },
          "recommendation": "Consider an alternative agent particularly where jaundice would be of concern to the patient. If atazanavir is to be prescribed, there is a high likelihood of developing jaundice that will result in atazanavir discontinuation (at least 20% and as high as 60%).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-atazanavir-and-ugt1a1/"
        }
      ],
      "atomoxetine": [
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and increase to 1.2 mg/kg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If < 200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Initiate with a dose of 0.5 mg/kg/day and if no clinical response and in the absence of adverse events after 2 weeks, consider obtaining a plasma concentration 4 hours after dosing. If response is inadequate and concentration is < 200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and increase to 80 mg/day after 3 days. If no clinical response and in the absence of adverse events after 2 weeks, consider increasing dose to 100 mg/day. If no clinical response observed after 2 weeks, consider obtaining a peak plasma concentration (1 to 2 hours after dose administered). If <200 ng/mL, consider a proportional increase in dose to approach 400 ng/mL. Dosages greater than 100 mg/day may be needed to achieve target concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks consider obtaining a plasma concentration 2-4 h after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Initiate with a dose of 40 mg/day and if no clinical response and in the absence of adverse events after 2 weeks increase dose to 80 mg/day. If response is inadequate after 2 weeks, consider obtaining a plasma concentration 2 to 4 hours after dosing. If concentration is <200 ng/mL, consider a proportional dose increase to achieve a concentration to approach 400 ng/mL. If unacceptable side effects are present at any time, consider a reduction in dose.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-atomoxetine-based-on-cyp2d6-genotype/"
        }
      ],
      "azathioprine": [
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "NUDT15 phenotype could not be assigned based on genotyping performed and no TPMT genotype is available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignant conditions, start with drastically reduced normal daily doses (reduce daily dose by 10-fold) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is 2-3 mg/kg/day (e.g., 0.6 \u2013 2.4 mg/kg/day), and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with normal starting dose (e.g., 2-3 mg/kg/day) and adjust doses of azathioprine based on disease-specific guidelines. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11302950, 15606506). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, for non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy. For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of azathioprine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment (PMID 16530578, 11302950, 15606506, 16530532, 12477776). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        }
      ],
      "carbamazepine": [
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve and alternative agents are available, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve and alternative agents are available, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve and alternative agents are not available, consider the use of carbamazepine with increased frequency of clinical monitoring. Discontinue therapy at first evidence of a cutaneous adverse reaction.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is carbamazepine-na\u00efve, do not use carbamazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine in the future.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "Use carbamazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "The latency period for cutaneous adverse drug reactions is variable depending on phenotype; however, all usually occur within three months of regular dosing. Therefore, if the patient has previously used carbamazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of carbamazepine.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        }
      ],
      "lornoxicam": [
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "celecoxib": [
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "flurbiprofen": [
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "ibuprofen": [
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Initiate therapy with lowest recommended starting dose. Titrate dose upward to clinical effect or maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Carefully monitor adverse events such as blood pressure and kidney function during course of therapy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Initiate therapy with 25-50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 25-50% of the maximum recommended dose with caution. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 8 days for celecoxib after first dose in PMs). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider an alternate therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "citalopram": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Consider an alternative drug not predominantly metabolized by CYP2C19",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "clomipramine": [
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use. If a clomipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid clomipramine use; If clomipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "clopidogrel": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Clopidogrel: label-recommended dosage and administration",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Clopidogrel: label-recommended dosage and administration",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Clopidogrel: label-recommended dosage and administration",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Alternative antiplatelet therapy (if no contraindication); e.g., prasugrel, ticagrelor",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-clopidogrel-and-cyp2c19/"
        }
      ],
      "desflurane": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "enflurane": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "desipramine": [
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "halothane": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "doxepin": [
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use. If a doxepin is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid doxepin use; If doxepin is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "isoflurane": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "methoxyflurane": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "sevoflurane": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "succinylcholine": [
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Halogenated volatile anesthetics or the depolarizing muscle relaxant succinylcholine are relatively contraindicated in persons with malignant hyperthermia susceptibility (MHS). They should not be used, except in extraordinary circumstances where the benefits outweigh the risks. In general, alternative anesthetics are widely available and effective in patients with MHS.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        },
        {
          "factors": {},
          "recommendation": "Clinical findings, family history, further genetic testing and other laboratory data should guide use of halogenated volatile anesthetics or depolarizing muscle relaxants.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-ryr1-and-cacna1s/"
        }
      ],
      "hydrocodone": [
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine or non-tramadol opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Use hydrocodone label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine and non-tramadol opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "No recommendation for hydrocodone therapy because of minimal evidence regarding adverse events or analgesia.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        }
      ],
      "dexlansoprazole": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        }
      ],
      "imipramine": [
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If a imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use. If imipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid imipramine use; If imipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "efavirenz": [
        {
          "factors": {
            "CYP2B6": "Ultrarapid Metabolizer"
          },
          "recommendation": "Initiate efavirenz with standard dosing (600 mg/day)",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"
        },
        {
          "factors": {
            "CYP2B6": "Rapid Metabolizer"
          },
          "recommendation": "Initiate efavirenz with standard dosing (600 mg/day)",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"
        },
        {
          "factors": {
            "CYP2B6": "Normal Metabolizer"
          },
          "recommendation": "Initiate efavirenz with standard dosing (600 mg/day)",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"
        },
        {
          "factors": {
            "CYP2B6": "Intermediate Metabolizer"
          },
          "recommendation": "Consider initiating efavirenz with decreased dose of 400 mg/day",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"
        },
        {
          "factors": {
            "CYP2B6": "Poor Metabolizer"
          },
          "recommendation": "Consider initiating efavirenz with decreased dose of 400 or 200 mg/day",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-efavirenz-based-on-cyp2b6-genotype/"
        }
      ],
      "fluorouracil": [
        {
          "factors": {
            "DPYD": "== 2.00"
          },
          "recommendation": "Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 1.50"
          },
          "recommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 1.00"
          },
          "recommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 0.50"
          },
          "recommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 0.00"
          },
          "recommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        }
      ],
      "capecitabine": [
        {
          "factors": {
            "DPYD": "== 2.00"
          },
          "recommendation": "Based on genotype, there is no indication to change dose or therapy. Use label-recommended dosage and administration.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 1.50"
          },
          "recommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 1.00"
          },
          "recommendation": "Reduce starting dose by 50% followed by titration of dose based on toxicity or therapeutic drug monitoring (if available).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 0.50"
          },
          "recommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens. In the event, based on clinical advice, alternative agents are not considered a suitable therapeutic option, 5-fluorouracil should be administered at a strongly reduced dose with early therapeutic drug monitoring.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        },
        {
          "factors": {
            "DPYD": "== 0.00"
          },
          "recommendation": "Avoid use of 5-fluorouracil or 5-fluorouracil prodrug-based regimens.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-fluoropyrimidines-and-dpyd/"
        }
      ],
      "tramadol": [
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Avoid tramadol use because of possibility of diminished analgesia. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing. If no response and opioid use is warranted, consider non-codeine opioid.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Use tramadol label recommended age- or weight-specific dosing.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Avoid tramadol use because of potential for toxicity. If opioid use is warranted, consider a non-codeine opioid.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/"
        }
      ],
      "meloxicam": [
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Initiate therapy with 50% of the lowest recommended starting dose. Titrate dose upward to clinical effect or 50% of the maximum recommended dose with caution. In accordance with the meloxicam prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals. Upward dose titration should not occur until after steady state is reached (at least 7 days). Carefully monitor adverse events such as blood pressure and kidney function during course of therapy. Alternatively, consider alternative therapy. Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "ivacaftor": [
        {
          "factors": {
            "CFTR": "ivacaftor non-responsive in CF patients"
          },
          "recommendation": "Ivacaftor is not recommended",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"
        },
        {
          "factors": {
            "CFTR": "ivacaftor responsive in CF patients"
          },
          "recommendation": "Use ivacaftor according to the product label",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ivacaftor-and-cftr/"
        }
      ],
      "mercaptopurine": [
        {
          "factors": {},
          "recommendation": "Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype result result. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "TPMT phenotype could not be assigned based on genotyping performed and there is no NUDT15 genotype result available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, for malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). NUDT15 genotype result is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u226575 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u226575 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u226575 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g. start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with normal starting dose (e.g., 75 mg/m2/day or 1.5 mg/kg/day) and adjust doses of mercaptopurine (and of any other myelosuppressive therapy) without any special emphasis on mercaptopurine compared to other agents. Allow at least 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 16401827, 11302950). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, for malignancy, initiate dose at 10 mg/m2/day and adjust dose based on myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532). TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u226575 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u2265 75 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201,18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u226575 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "For malignancy, start with drastically reduced doses (reduce daily dose by 10-fold and reduce frequency to thrice weekly instead of daily, e.g., 10 mg/m2/day given just 3 days/week) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing mercaptopurine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201, 1960624, 11302950, 16530532).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15 status, start with reduced starting doses (30%-80% of normal dose) if normal starting dose is \u226575 mg/m2/day or \u2265 1.5 mg/kg/day (e.g., start at 22.5-60 mg/m2/day or 0.45-1.2 mg/kg/day) and adjust doses of mercaptopurine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing mercaptopurine over other agents (PMID 20354201, 18685564, 8857546, 18987654, 20010622, 16401827, 11302950, 16530532, 9634537). If normal starting dose is already < 75 mg/m2/day or < 1.5 mg/kg/day, dose reduction may not be recommended. TPMT genotype result is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        }
      ],
      "nortriptyline": [
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Consider a 25% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a tricyclic antidepressant is warranted, consider a 50% reduction of recommended starting dose. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "paroxetine": [
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 or if paroxetine use warranted, consider a 50% reduction of recommended starting dose and titrate to response.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "omeprazole": [
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        }
      ],
      "lansoprazole": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        }
      ],
      "pantoprazole": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Increase starting daily dose by 100%. Daily dose may be given in divided doses. Monitor for efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. Consider increasing dose by 50-100% for the treatment of H. pylori infection and erosive esophagitis. Daily dose may be given in divided doses.\nMonitor for efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Initiate standard starting daily dose. For chronic therapy (>12 weeks) and efficacy achieved, consider 50% reduction in daily dose and monitor for continued efficacy.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-proton-pump-inhibitors-and-cyp2c19/"
        }
      ],
      "ondansetron": [
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        }
      ],
      "tropisetron": [
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Select alternative drug not predominantly metabolized by CYP2D6 (i.e., granisetron).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Insufficient evidence demonstrating clinical impact based on CYP2D6 genotype. Initiate therapy with recommended starting dose.",
          "strength": null,
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-ondansetron-and-tropisetron-and-cyp2d6-genotype/"
        }
      ],
      "oxcarbazepine": [
        {
          "factors": {
            "HLA-B*15:02": "negative"
          },
          "recommendation": "Use oxcarbazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {
            "HLA-B*15:02": "positive"
          },
          "recommendation": "If patient is oxcarbazepine-na\u00efve, do not use oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {
            "HLA-B*15:02": "negative"
          },
          "recommendation": "Use oxcarbazepine per standard dosing guidelines.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        },
        {
          "factors": {
            "HLA-B*15:02": "positive"
          },
          "recommendation": "The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (~4-28 days), and cases usually occur within three months of dosing; therefore, if the patient has previously used oxcarbazepine consistently for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of oxcarbazepine in the future.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-carbamazepine-and-hla-b/"
        }
      ],
      "phenytoin": [
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        }
      ],
      "fosphenytoin": [
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If patient is phenytoin-naive, do not use phenytoin/fosphenytoin. Avoid carbamazepine and oxcarbazepine.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "No adjustments needed from typical dosing strategies. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses, use approximately 25% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "For first dose, use typical initial or loading dose. For subsequent doses use approximately 50% less than typical maintenance dose. Subsequent doses should be adjusted according to therapeutic drug monitoring, response, and side effects. An HLA-B*15:02 negative test does not eliminate the risk of phenytoin-induced SJS/TEN, and patients should be carefully monitored according to a usual standard.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        },
        {
          "factors": {},
          "recommendation": "If the patient has previously used phenytoin continuously for longer than three months without incidence of cutaneous adverse reactions, cautiously consider use of phenytoin in the future. The latency period for drug-induced SJS/TEN is short with continuous dosing and adherence to therapy (4-28 days), and cases usually occur within three months of dosing.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-phenytoin-and-cyp2c9-and-hla-b/"
        }
      ],
      "tamoxifen": [
        {
          "factors": {
            "CYP2D6": "== 1.25"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 6.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 5.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.50"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 4.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.50"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.25"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": ">= 3.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 4.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.50"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 3.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.50"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.25"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 2.00"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.75"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.50"
          },
          "recommendation": "Avoid moderate and strong CYP2D6 inhibitors. Initiate therapy with recommended standard of care dosing (tamoxifen 20 mg/day).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 1.00"
          },
          "recommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.75"
          },
          "recommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.50"
          },
          "recommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.25"
          },
          "recommendation": "Consider hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women, given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827). If aromatase inhibitor use is contraindicated, consideration should be given to use a higher but FDA approved tamoxifen dose (40 mg/day)(PMID 27226358). Avoid CYP2D6 strong to weak inhibitors.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        },
        {
          "factors": {
            "CYP2D6": "== 0.00"
          },
          "recommendation": "Recommend alternative hormonal therapy such as an aromatase inhibitor for postmenopausal women or aromatase inhibitor along with ovarian function suppression in premenopausal women given that these approaches are superior to tamoxifen regardless of CYP2D6 genotype (PMID 26211827) and based on knowledge that CYP2D6 poor metabolizers switched from tamoxifen to anastrozole do not have an increased risk of recurrence (PMID 23213055). Note, higher dose tamoxifen (40 mg/day) increases but does not normalize endoxifen concentrations and can be considered if there are contraindications to aromatase inhibitor therapy (PMID 27226358, 21768473).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-tamoxifen-based-on-cyp2d6-genotype/"
        }
      ],
      "piroxicam": [
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "rasburicase": [
        {
          "factors": {
            "G6PD": "Normal"
          },
          "recommendation": "No reason to withhold rasburicase based on G6PD status.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"
        },
        {
          "factors": {
            "G6PD": "Variable"
          },
          "recommendation": "To ascertain that G6PD status is normal, enzyme activity must be measured; alternatives include allopurinol.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"
        },
        {
          "factors": {
            "G6PD": "Deficient"
          },
          "recommendation": "Rasburicase is contraindicated; alternatives include allopurinol.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-rasburicase-and-g6pd/"
        }
      ],
      "sertraline": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose. If patient does not respond to recommended maintenance dosing, consider alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended starting dose",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Consider a 50% reduction of recommended starting dose and titrate to response or select alternative drug not predominantly metabolized by CYP2C19.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-selective-serotonin-reuptake-inhibitors-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "simvastatin": [
        {
          "factors": {
            "SLCO1B1": "Normal function"
          },
          "recommendation": "Prescribe desired starting dose and adjust doses of simvastatin based on disease-specific guidelines",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"
        },
        {
          "factors": {
            "SLCO1B1": "possible decreased function"
          },
          "recommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"
        },
        {
          "factors": {
            "SLCO1B1": "Decreased function"
          },
          "recommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"
        },
        {
          "factors": {
            "SLCO1B1": "possible poor function"
          },
          "recommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"
        },
        {
          "factors": {
            "SLCO1B1": "Poor function"
          },
          "recommendation": "Prescribe a lower dose or consider an alternative statin (e.g., pravastatin or rosuvastatin); consider routine creatine kinase surveillance.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-simvastatin-and-slco1b1/"
        }
      ],
      "tacrolimus": [
        {
          "factors": {
            "CYP3A5": "Normal Metabolizer"
          },
          "recommendation": "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"
        },
        {
          "factors": {
            "CYP3A5": "Possible Intermediate Metabolizer"
          },
          "recommendation": "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"
        },
        {
          "factors": {
            "CYP3A5": "Intermediate Metabolizer"
          },
          "recommendation": "Increase starting dose 1.5 to 2 times recommended starting dose. Total starting dose should not exceed 0.3 mg/kg/day. Use therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"
        },
        {
          "factors": {
            "CYP3A5": "Poor Metabolizer"
          },
          "recommendation": "Initiate therapy with standard recommended dose. Use therapeutic drug monitoring to guide dose adjustments.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tacrolimus-and-cyp3a5/"
        }
      ],
      "tenoxicam": [
        {
          "factors": {
            "CYP2C9": "== 2.00"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.50"
          },
          "recommendation": "Initiate therapy with recommended starting dose. In accordance with the prescribing information, use the lowest effective dosage for shortest duration consistent with individual patient treatment goals.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 1.00"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.50"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        },
        {
          "factors": {
            "CYP2C9": "== 0.00"
          },
          "recommendation": "Choose an alternative therapy not metabolized by CYP2C9 or not significantly impacted by CYP2C9 genetic variants in vivo or choose an NSAID metabolized by CYP2C9 but with a shorter half-life (see CPIC THERAPEUTIC RECOMMENDATIONS FOR CELECOXIB, FLURBIPROFEN, LORNOXICAM, AND IBUPROFEN BASED ON CYP2C9 PHENOTYPE).",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/cpic-guideline-for-nsaids-based-on-cyp2c9-genotype/"
        }
      ],
      "thioguanine": [
        {
          "factors": {},
          "recommendation": "Neither TPMT or NUDT15 phenotype could be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT phenotype could not be assigned based on genotyping performed. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "TPMT phenotype could not be assigned based on genotyping performed and NUDT15 genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "NUDT15 phenotype could not be assigned based on genotyping performed and there is no TPMT genotype available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857). However, TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). TPMT genotype is not available. Consider evaluating TPMT erythrocyte activity to assess TPMT phenotype. If thiopurines are required and TPMT status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on NUDT15, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). TPMT genotype is not available. Consider evaluating erythrocyte TPMT activity to assess TPMT phenotype. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and either TPMT or NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 phenotype could not be assigned based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 20354201, 11037857).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Reduce starting doses to 25% of normal dose and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. In setting of myelosuppression, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with reduced doses (50% to 80% of normal dose) if normal starting dose is \u2265 40-60 mg/m2/day (e.g., 20-48 mg/m2/day) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 2-4 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, and depending on other therapy, emphasis should be on reducing thioguanine over other agents (PMID 20354201, 11037857).",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with normal starting dose (e.g., 40-60 mg/m2/day) and adjust doses of thioguanine and of other myelosuppressive therapy without any special emphasis on thioguanine. Allow 2 weeks to reach steady-state after each dose adjustment (PMID 203542+J1301, 11037857). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 status could not be determined based on genotyping. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201).",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        },
        {
          "factors": {},
          "recommendation": "Based on TPMT status, start with drastically reduced doses (PMID 11037857) (reduce daily dose by 10-fold and dose thrice weekly instead of daily) and adjust doses of thioguanine based on degree of myelosuppression and disease-specific guidelines. Allow 4-6 weeks to reach steady-state after each dose adjustment. If myelosuppression occurs, emphasis should be on reducing thioguanine over other agents. For non-malignant conditions, consider alternative non-thiopurine immunosuppressant therapy (PMID 20354201). NUDT15 genotype is not available. If thiopurines are required and NUDT15 status is unknown, monitor closely for toxicity.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/"
        }
      ],
      "trimipramine": [
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider a 25% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Consider alternative drug not metabolized by CYP2C19; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use. If a trimipramine is warranted, consider a 50% reduction of recommended starting dose. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential for side effects. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider a 50% reduction of recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustment.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid trimipramine use; If trimipramine is warranted, utilize therapeutic drug monitoring to guide dose adjustment. Utilizing therapeutic drug monitoring to guide dose adjustments is strongly recommended.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tricyclic use due to potential lack of efficacy. Consider alternative drug not metabolized by CYP2D6. If a TCA is warranted, consider titrating to a higher target dose (compared to normal metabolizers). Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. If a tertiary amine is warranted, utilize therapeutic drug monitoring to guide dose adjustments.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Initiate therapy with recommended starting dose.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        },
        {
          "factors": {},
          "recommendation": "Avoid tertiary amine use due to potential for sub-optimal response. Consider alternative drug not metabolized by CYP2C19. TCAs without major CYP2C19 metabolism include the secondary amines nortriptyline and desipramine. For tertiary amines, consider a 50% reduction of the recommended starting dose. Utilize therapeutic drug monitoring to guide dose adjustments. Titrate dose to observed clinical response with symptom improvement and minimal (if any) side effects.",
          "strength": "optional",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-tricyclic-antidepressants-and-cyp2d6-and-cyp2c19/"
        }
      ],
      "voriconazole": [
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing. Use therapeutic drug monitoring to titrate dose to therapeutic trough concentrations.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include liposomal amphotericin B and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Ultrarapid Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Rapid Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Normal Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing",
          "strength": "strong",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Intermediate Metabolizer"
          },
          "recommendation": "Initiate therapy with recommended standard of care dosing",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Likely Poor Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        },
        {
          "factors": {
            "CYP2C19": "Poor Metabolizer"
          },
          "recommendation": "Choose an alternative agent that is not dependent on CYP2C19 metabolism as primary therapy in lieu of voriconazole. Such agents include isavuconazole, liposomal amphotericin B, and posaconazole. In the event that voriconazole is considered to be the most appropriate agent, based on clinical advice, for a patient with poor metabolizer genotype, voriconazole should be administered at a preferably lower than standard dosage with careful therapeutic drug monitoring.",
          "strength": "moderate",
          "guideline": "https://cpicpgx.org/guidelines/guideline-for-voriconazole-and-cyp2c19/"
        }
      ]
    },
    "dpwg": {
      "irinotecan": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104951"
          }
        ]
      ],
      "mercaptopurine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166184613"
          },
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104952"
          }
        ]
      ],
      "zuclopenthixol": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104992"
          }
        ]
      ],
      "flucytosine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166222801"
          }
        ]
      ],
      "acenocoumarol": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104938"
          }
        ]
      ],
      "pimozide": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182819"
          }
        ]
      ],
      "thioguanine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104960"
          },
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166184612"
          }
        ]
      ],
      "flucloxacillin": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182810"
          }
        ]
      ],
      "use": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104955"
          }
        ]
      ],
      "fluorouracil": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104939"
          }
        ]
      ],
      "brexpiprazole": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166184527"
          }
        ]
      ],
      "haloperidol": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104988"
          }
        ]
      ],
      "sertraline": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104980"
          }
        ]
      ],
      "azathioprine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166184614"
          },
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104934"
          }
        ]
      ],
      "warfarin": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182842"
          },
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182841"
          }
        ]
      ],
      "atorvastatin": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182843"
          }
        ]
      ],
      "imipramine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104972"
          },
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104954"
          }
        ]
      ],
      "siponimod": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166211021"
          }
        ]
      ],
      "propafenone": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104962"
          }
        ]
      ],
      "doxepin": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104994"
          }
        ]
      ],
      "nortriptyline": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104961"
          }
        ]
      ],
      "lansoprazole": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104987"
          }
        ]
      ],
      "aripiprazole": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104937"
          }
        ]
      ],
      "atomoxetine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104989"
          }
        ]
      ],
      "clopidogrel": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104956"
          }
        ]
      ],
      "voriconazole": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104990"
          }
        ]
      ],
      "abacavir": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104991"
          }
        ]
      ],
      "metoprolol": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104995"
          }
        ]
      ],
      "clomipramine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104964"
          },
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166184528"
          }
        ]
      ],
      "efavirenz": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182846"
          }
        ]
      ],
      "tamoxifen": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104966"
          }
        ]
      ],
      "capecitabine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104963"
          }
        ]
      ],
      "flecainide": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104969"
          }
        ]
      ],
      "amitriptyline": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104982"
          }
        ]
      ],
      "pantoprazole": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104958"
          }
        ]
      ],
      "tramadol": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104959"
          }
        ]
      ],
      "citalopram": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104977"
          }
        ]
      ],
      "escitalopram": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104975"
          }
        ]
      ],
      "simvastatin": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182844"
          }
        ]
      ],
      "omeprazole": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104957"
          }
        ]
      ],
      "risperidone": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104943"
          }
        ]
      ],
      "phenprocoumon": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104940"
          }
        ]
      ],
      "eliglustat": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166182823"
          }
        ]
      ],
      "tacrolimus": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104983"
          }
        ]
      ],
      "paroxetine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104976"
          }
        ]
      ],
      "phenytoin": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104984"
          }
        ]
      ],
      "tegafur": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104944"
          }
        ]
      ],
      "codeine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104970"
          }
        ]
      ],
      "venlafaxine": [
        [
          {
            "factors": {},
            "recommendation": "NO action is needed for this gene-drug interaction.",
            "guideline": "https://pharmgkb.org/guidelineAnnotation/PA166104968"
          }
        ]
      ]
    },
    "fda": {
      "abacavir": [
        {
          "factors": {
            "HLA-B*57:01": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (hypersensitivity reactions). Do not use abacavir in patients positive for HLA-B*57:01.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "amifampridine": [
        {
          "factors": {
            "NAT2": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Use lowest recommended starting dosage and monitor for adverse reactions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "amifampridine phosphate": [
        {
          "factors": {
            "NAT2": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Use lowest recommended starting dosage (15 mg/day) and monitor for adverse reactions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "amphetamine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May affect systemic concentrations and adverse reaction risk. Consider lower starting dosage or use alternative agent.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "aripiprazole": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "aripiprazole lauroxil": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "atomoxetine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Adjust titration interval and increase dosage if tolerated. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "azathioprine": [
        {
          "factors": {
            "TPMT and/or NUDT15": "intermediate metabolizer"
          },
          "recommendation": "Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "TPMT and/or NUDT15": "poor metabolizer"
          },
          "recommendation": "Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Consider alternative therapy in poor metabolizers. Dosage reduction is recommended in intermediate metabolizers for NUDT15 or TPMT. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "belinostat": [
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and higher adverse reaction risk. Reduce starting dose to 750 mg/m2 in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "brexpiprazole": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "brivaracetam": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Consider dosage reductions in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "capecitabine": [
        {
          "factors": {
            "DPYD": "intermediate metabolizer"
          },
          "recommendation": "Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers, and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "DPYD": "poor metabolizer"
          },
          "recommendation": "Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers, and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "carbamazepine": [
        {
          "factors": {
            "HLA-B*15:02": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (severe skin reactions). Avoid use unless potential benefits outweigh risks and consider risks of alternative therapies. Patients positive for HLA-B*15:02 may be at increased risk of severe skin reactions with other drugs that are associated with a risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Genotyping is not a substitute for clinical vigilance.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "HLA-A*31:01": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (severe skin reactions). Consider risk and benefit of carbamazepine use in patients positive for HLA-A*31:01. Genotyping is not a substitute for clinical vigilance.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "celecoxib": [
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Reduce starting dose to half of the lowest recommended dose in poor metabolizers. Consider alternative therapy in patients with juvenile rheumatoid arthritis.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "citalopram": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dose is 20 mg.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "clobazam": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic active metabolite concentrations. Poor metabolism results in higher adverse reaction risk. Dosage adjustment is recommended. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "clopidogrel": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in lower systemic active metabolite concentrations, lower antiplatelet response, and may result in higher cardiovascular risk. Consider use of another platelet P2Y12 inhibitor.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "clozapine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Dosage reductions may be necessary.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "codeine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "Results in higher systemic active metabolite concentrations and higher adverse reaction risk (life-threatening respiratory depression and death). Codeine is contraindicated in children under 12 years of age.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in lower systemic active metabolite concentrations and may result in reduced efficacy.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "deutetrabenazine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and adverse reaction risk (QT prolongation). The maximum recommended dosage should not exceed 36 mg (maximum single dose of 18 mg).",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "dronabinol": [
        {
          "factors": {
            "CYP2C9": "intermediate metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "eliglustat": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "normal metabolizer"
          },
          "recommendation": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Alters systemic concentrations, effectiveness, and adverse reaction risk (QT prolongation). Indicated for normal, intermediate, and poor metabolizer patients. Ultrarapid metabolizers may not achieve adequate concentrations to achieve a therapeutic effect. The recommended dosages are based on CYP2D6 metabolizer status. Coadministration with strong CYP3A inhibitors is contraindicated in intermediate and poor CYP2D6 metabolizers. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "erdafitinib": [
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "flibanserin": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and higher adverse reaction risk. Monitor patients for adverse reactions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "flurbiprofen": [
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Use a reduced dosage.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "fluorouracil": [
        {
          "factors": {
            "DPYD": "intermediate metabolizer"
          },
          "recommendation": "Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "DPYD": "poor metabolizer"
          },
          "recommendation": "Results in higher adverse reaction risk (severe, life-threatening, or fatal toxicities). No dosage has proven safe in poor metabolizers and insufficient data are available to recommend a dosage in intermediate metabolizers. Withhold or discontinue in the presence of early-onset or unusually severe toxicity.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "gefitinib": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Monitor for adverse reactions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "iloperidone": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Reduce dosage by 50%.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "irinotecan": [
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic active metabolite concentrations and higher adverse reaction risk (severe neutropenia). Consider reducing the starting dosage by one level and modify the dosage based on individual patient tolerance.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "lofexidine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. Monitor for orthostatic hypotension and bradycardia.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "meclizine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May affect systemic concentrations. Monitor for adverse reactions and clinical effect.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "meloxicam": [
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Consider dose reduction.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "metoclopramide": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk. The recommended dosage is lower. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "mercaptopurine": [
        {
          "factors": {
            "TPMT and/or NUDT15": "intermediate metabolizer"
          },
          "recommendation": "Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "TPMT and/or NUDT15": "poor metabolizer"
          },
          "recommendation": "Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "mivacurium": [
        {
          "factors": {
            "BCHE": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (prolonged neuromuscular blockade). Avoid use in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "BCHE": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (prolonged neuromuscular blockade). Avoid use in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "pantoprazole": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Consider dosage reduction in children who are poor metabolizers. No dosage adjustment is needed for adult patients who are poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "pimozide": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Dosages should not exceed 0.05 mg/kg in children or 4 mg/day in adults who are poor metabolizers and dosages should not be increased earlier than 14 days.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "piroxicam": [
        {
          "factors": {
            "CYP2C9": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Consider reducing dosage in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "pitolisant": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Use lowest recommended starting dosage. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "propafenone": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (arrhythmia). Avoid use in poor metabolizers taking a CYP3A4 inhibitor.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "sacituzumab govitecan-hziy": [
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and adverse reaction risk (neutropenia). Monitor for adverse reactions and tolerance to treatment.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "siponimod": [
        {
          "factors": {
            "CYP2C9": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Adjust dosage based on genotype. Do not use in patients with CYP2C9 *3/*3 genotype. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "succinylcholine": [
        {
          "factors": {
            "BCHE": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (prolonged neuromuscular blockade). Avoid use in poor metabolizers. May administer test dose to assess sensitivity and administer cautiously via slow infusion.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "BCHE": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (prolonged neuromuscular blockade). Avoid use in poor metabolizers. May administer test dose to assess sensitivity and administer cautiously via slow infusion.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "tacrolimus": [
        {
          "factors": {
            "CYP3A5": "intermediate metabolizer"
          },
          "recommendation": "Results in lower systemic concentrations, lower probability of achieving target concentrations and may result in higher rejection risk. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP3A5": "normal metabolizer"
          },
          "recommendation": "Results in lower systemic concentrations, lower probability of achieving target concentrations and may result in higher rejection risk. Measure drug concentrations and adjust dosage based on trough whole blood tacrolimus concentrations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "tetrabenazine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. The maximum recommended single dose is 25 mg and should not exceed 50 mg/day.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "thioguanine": [
        {
          "factors": {
            "TPMT and/or NUDT15": "intermediate metabolizer"
          },
          "recommendation": "Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "TPMT and/or NUDT15": "poor metabolizer"
          },
          "recommendation": "Alters systemic active metabolite concentration and dosage requirements. Results in higher adverse reaction risk (myelosuppression). Initial dosages should be reduced in poor metabolizers; poor metabolizers generally tolerate 10% or less of the recommended dosage. Intermediate metabolizers may require dosage reductions based on tolerability. Intermediate metabolizers for both genes may require more substantial dosage reductions. Refer to FDA labeling for specific dosing recommendations.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "thioridazine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation). Predicted effect based on experience with CYP2D6 inhibitors. Contraindicated in poor metabolizers.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "tramadol": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "Results in higher systemic and breast milk active metabolite concentrations, which may result in respiratory depression and death. Contraindicated in children under 12 and in adolescents following tonsillectomy/adenoidectomy. Breastfeeding is not recommended during treatment.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "valbenazine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic active metabolite concentrations and higher adverse reaction risk (QT prolongation). Dosage reductions may be necessary.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "venlafaxine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Alters systemic parent drug and metabolite concentrations. Consider dosage reductions.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "vortioxetine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. The maximum recommended dose is 10 mg.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "warfarin": [
        {
          "factors": {
            "CYP2C9": "intermediate metabolizer"
          },
          "recommendation": "Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Alters systemic concentrations and dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP4F2": "*3 (rs2108622 T, V433M)"
          },
          "recommendation": "May affect dosage requirements. Monitor and adjust doses based on INR.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "VKORC1": "rs9923231 reference (C)"
          },
          "recommendation": "Alters dosage requirements. Select initial dosage, taking into account clinical and genetic factors. Monitor and adjust dosages based on INR.",
          "strength": "strong",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "allopurinol": [
        {
          "factors": {
            "HLA-B*58:01": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (severe skin reactions).",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "carvedilol": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (dizziness).",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "cevimeline": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May result in higher adverse reaction risk. Use with caution.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "efavirenz": [
        {
          "factors": {
            "CYP2B6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "isoniazid": [
        {
          "factors": {
            "Nonspecific (NAT)": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations and adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "lapatinib": [
        {
          "factors": {
            "HLA-DRB1*07:01": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (hepatotoxicity). Monitor liver function tests regardless of genotype.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "HLA-DQA1*02:01": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (hepatotoxicity). Monitor liver function tests regardless of genotype.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "nilotinib": [
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "Results in higher adverse reaction risk (hyperbilirubinemia).",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "oxcarbazepine": [
        {
          "factors": {
            "HLA-B*15:02": "positive"
          },
          "recommendation": "Results in higher adverse reaction risk (severe skin reactions). Patients positive for HLA-B*15:02 may be at increased risk of severe skin reactions with other drugs that are associated with a risk of Stevens Johnson Syndrome/Toxic Epidermal necrolysis (SJS/TEN). Genotyping is not a substitute for clinical vigilance.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "pazopanib": [
        {
          "factors": {
            "HLA-B*57:01": "positive"
          },
          "recommendation": "May result in higher adverse reaction risk (liver enzyme elevations). Monitor liver function tests regardless of genotype.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "Results in higher adverse reaction risk (hyperbilirubinemia).",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "perphenazine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "procainamide": [
        {
          "factors": {
            "Nonspecific (NAT)": "poor metabolizer"
          },
          "recommendation": "Alters systemic parent drug and metabolite concentrations. May result in higher adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "simvastatin": [
        {
          "factors": {
            "SLCO1B1": "521 TC"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "SLCO1B1": "521 CC"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "SLCO1B1": "intermediate function"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "SLCO1B1": "poor function"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (myopathy). The risk of adverse reaction (myopathy) is higher for patients on 80 mg than for those on lower doses.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "sulfamethoxazole and trimethoprim": [
        {
          "factors": {
            "Nonspecific (NAT)": "poor metabolizer"
          },
          "recommendation": "May result in higher adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "sulfasalazine": [
        {
          "factors": {
            "Nonspecific (NAT)": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic metabolite concentrations and higher adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "tolterodine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and higher adverse reaction risk (QT prolongation).",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "voriconazole": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and may result in higher adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations and may result in higher adverse reaction risk.",
          "strength": "moderate",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "amitriptyline": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "amoxapine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "atorvastatin": [
        {
          "factors": {
            "SLCO1B1": "521 CC"
          },
          "recommendation": "May result in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "SLCO1B1": "poor function"
          },
          "recommendation": "May result in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "avatrombopag": [
        {
          "factors": {
            "CYP2C9": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C9": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "carisoprodol": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Use with caution.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "clomipramine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "darifenacin": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "desipramine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "dexlansoprazole": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "diazepam": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "May affect systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "dolutegravir": [
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "donepezil": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "Alters systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Alters systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "doxepin": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "elagolix": [
        {
          "factors": {
            "SLCO1B1": "521 CC"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "SLCO1B1": "poor function"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "escitalopram": [
        {
          "factors": {
            "CYP2C19": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "esomeprazole": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "fesoterodine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic active metabolite concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "fluvoxamine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Use with caution.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "galantamine": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Titrate dosage based on tolerability.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "hydralazine": [
        {
          "factors": {
            "Nonspecific (NAT)": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "imipramine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "metoprolol": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "mirabegron": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "nebivolol": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May result in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "nortriptyline": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "omeprazole": [
        {
          "factors": {
            "CYP2C19": "intermediate metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "paroxetine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "propranolol": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May affect systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "protriptyline": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "rabeprazole": [
        {
          "factors": {
            "CYP2C19": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "raltegravir": [
        {
          "factors": {
            "UGT1A1": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "risperidone": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Alters systemic parent drug and metabolite concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "rosuvastatin": [
        {
          "factors": {
            "SLCO1B1": "521 CC"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "SLCO1B1": "poor function"
          },
          "recommendation": "Results in higher systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "tamoxifen": [
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in lower systemic active metabolite concentrations. The impact of CYP2D6 intermediate or poor metabolism on efficacy is not well established.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "tamsulosin": [
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "Results in higher systemic concentrations. Predicted effect based on experience with CYP2D6 inhibitors. Use with caution.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ],
      "trimipramine": [
        {
          "factors": {
            "CYP2D6": "ultrarapid metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "intermediate metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        },
        {
          "factors": {
            "CYP2D6": "poor metabolizer"
          },
          "recommendation": "May alter systemic concentrations.",
          "strength": "optional",
          "guideline": "https://www.fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations"
        }
      ]
    }
  }
}